⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCRX News
BioCryst Pharmaceuticals Inc
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BCRX
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
globenewswire.com
BCRX
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events
businesswire.com
BCRX
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
globenewswire.com
BCRX
Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition
prnewswire.com
BCRX
Form 8-K
sec.gov
BCRX
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BCRX
Form 8-K
sec.gov
BCRX
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
globenewswire.com
BCRX